Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Overview
Analysis
Risks
Rating
Chart
Analysts
Street
Sentiment
Earnings
Headlines
UTHR
United Therapeutics Corpo
$338.22
1412
Overview
Analysis
Risks
Rating
Chart
Analysts
Street
Sentiment
Earnings
Headlines
UTHR Stock Rating Review
Login to display United Therapeutics Corpo (UTHR) recommendation from the last 90 days from financial news and social media.
UTHR Total Score
Strengths
Earnings are forecast to grow
Outperform the market
Risk Analysis
Downgraded on weak valued
Analysts lowered price target
Chart
288.06
258.13
233.97
220.67
UTHR Risk Level
This Indicator assigning UTHR risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.
Risk Volatility
UTHR has Low Risk Level
Click here to check what is your level of risk
UTHR Analysts Opinion
UTHR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Downgraded on weak valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Analysts lowered price target
Outperform the market
UTHR Analysts opinion is negative and has getting worse from the past 3 months
UTHR Street Consensus
Analysts perspectives on the stock desirability, trend direction, and growth potential.
Opinion
Score
Score
UTHR Street view is extremely ish and have positive views on the near-term outlook
UTHR Performance Sentiment
events present
events present
Bullish
Neutral
Bearish
Very Bearish
UTHR Earnings
The TTM reflects 12-month period, providing review of UTHR financial performance.
UTHR Financial Health
The company financial health has significantly improved over the past year, reflecting strong market demand and effective business strategies. Enhanced profitability and efficient cost management have contributed to this positive trend. The transition from a loss to profitability indicates a solid turnaround in operations, supported by better financial management.
Financial Score
SNY
Sanofi
52.40
-1.32%
REGN
Regeneron Pharmaceuticals
1078.63
+1.36%
AMGN
Amgen
334.85
+0.16%
ABBV
AbbVie
185.19
+1.64%
Explore our UTHR Stock insights
- In-Depth Market Analysis and Trends
- Expert Insights on Market Dynamics
- Tailored UTHR Stock Strategies
- Effective Risk Management
FIND US ON
Receive our UTHR Daily Alerts
Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses.
Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
